- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02615054
Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
All patients:
- Aged ≥ 18 years
- Female
- MSK histologically confirmed primary invasive breast carcinoma
- Pathologically confirmed HER2-positive breast cancer
- Treated with adjuvant trastuzumab (either alone or in combination with other anti-HER2 agents)
- ≥ 2 years since completion of targeted chemotherapy without evidence of disease
- Willing and able to comply with the requirements of the protocol
Patients in the cardiotoxicity (TOX) group must meet the following criteria:
- Development of treatment associated cardiotoxicity during trastuzumab therapy, defined as an absolute decrease from baseline in LVEF by ≥ 10%, to an LVEF of below 55%.
- No clinical signs or symptoms of heart failure (NYHA class III or IV) at the time of cardiotoxicity.
Note: NYHA Class III symptoms include marked limitation of physical activity. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain. NYHA Class IV symptoms include inability to carry on any physical activity without discomfort. Symptoms of heart failure or anginal syndrome may be present at rest, and if any physical activity is undertaken, discomfort is increased.
Patients in the no cardiotoxicity (NO-TOX) group must meet the following criteria:
- Maximum absolute decrease in LVEF ≤ 5% from baseline during trastuzumab therapy.
- Echocardiogram with LVEF assessment performed at baseline (prior to initiation of trastuzumab therapy) and at least two timepoints during trastuzumab therapy.
- LVEF ≥ 55% on each echocardiogram assessment during trastuzumab therapy.
- No clinical signs or symptoms of heart failure (NYHA class III or IV) during trastuzumab treatment.
Note: NYHA Class III symptoms include marked limitation of physical activity. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain. NYHA Class IV symptoms include inability to carry on any physical activity without discomfort. Symptoms of heart failure or anginal syndrome may be present at rest, and if any physical activity is undertaken, discomfort is increased.
Participants in the healthy control group must meet the following criteria:
- Aged ≥ 40 years
- Female
- No history of cancer with the exception of localized basal and/or squamous cell carcinoma of the skin
- No prior history of known cardiac disease (e.g. ischemic heart disease, heart failure, cardiomyopathy, or valvular heart disease [moderate to severe], or significant arrhythmias).
- Willing and able to comply with the requirements of the protocol
Exclusion Criteria:
- Inability to provide informed consent
- Presence of metastatic disease
- Treatment with additional cardiotoxic therapy for a secondary malignant neoplasm, or treatment with additional cardiotoxic therapy for breast cancer recurrence since primary breast cancer diagnosis [Note: Patients who are diagnosed with a second primary malignancy are not excluded from participation in the study, unless they meet this exclusion criterion.]
- Subjects must not have any of the following absolute contraindications to cardiopulmonary exercise testing : (a) acute myocardial infarction (within 3-5 days of any planned study procedures), (b) unstable angina, (c) uncontrolled arrhythmias causing symptoms or hemodynamic compromise, (d) symptomatic severe aortic stenosis, (e) recurrent syncope, (f) active endocarditis, (g) acute myocarditis or pericarditis, (h) uncontrolled heart failure, (i) acute pulmonary embolus or pulmonary infarction, (within 3 months of any planned study procedures), (j) thrombosis of lower extremities, (k) suspected dissecting aneurysm, (l) uncontrolled asthma, (m) pulmonary edema (within 3 months of planned study procedures), (n) room air desaturation at rest ≤85%, (o) respiratory failure, (p) acute noncardiopulmonary disorder that may affect exercise performance or be aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis), or (q) mental impairment leading to inability to cooperate.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
treated with trastuzmab no cardiac effects
|
All patients will undergo a two-dimensional echocardiogram with speckle tracking strain analysis within the MSK echocardiography laboratory.
To determine VO2peak, an electronic motorized treadmill test with 12-lead ECG monitoring (Mac ® 5000, GE Healthcare) will be performed by certified exercise physiologists.
|
treated with trastuzmab with cardiac effects
|
All patients will undergo a two-dimensional echocardiogram with speckle tracking strain analysis within the MSK echocardiography laboratory.
To determine VO2peak, an electronic motorized treadmill test with 12-lead ECG monitoring (Mac ® 5000, GE Healthcare) will be performed by certified exercise physiologists.
|
healthy volunteers no cancer treatment
|
All patients will undergo a two-dimensional echocardiogram with speckle tracking strain analysis within the MSK echocardiography laboratory.
To determine VO2peak, an electronic motorized treadmill test with 12-lead ECG monitoring (Mac ® 5000, GE Healthcare) will be performed by certified exercise physiologists.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cardiac function
Time Frame: 2 years
|
Exercise capacity will be assessed by CPET, and echocardiographic images will be obtained immediately after CPET to evaluate contractile reserve.
|
2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Anthony Yu, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-258
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trastuzumab Cardiotoxicity
-
Peking University Cancer Hospital & InstituteRecruitingHER2-positive Metastatic Breast Cancer | Previously Treated With Trastuzumab | Trastuzumab Combined With Pertuzumab and ChemotherapyChina
-
Peking University Third HospitalRecruitingBreast Cancer | Cardiotoxicity | Trastuzumab | Antitumor DrugsChina
-
Samsung Medical CenterRecruitingBreast Cancer | Cardiotoxicity | Prevention | Adjuvant | TrastuzumabKorea, Republic of
-
Centre Hospitalier Universitaire de BesanconCompletedMetastatic Cancer | HER2-positive Gastric Cancer | Docetaxel | TrastuzumabFrance
-
The Hospital for Sick ChildrenCanadian Institutes of Health Research (CIHR); London Health Sciences Centre; Children's Hospital of Eastern Ontario and other collaboratorsCompletedAnthracycline-induced CardiotoxicityUnited States, Canada
-
Cancer Institute and Hospital, Chinese Academy...RecruitingSafety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer (RADIOCOM)Chemotherapeutic Toxicity | Radiotherapy; Complications | PARP Inhibitor | Immune Checkpoint Inhibitor | Trastuzumab | Breast Cancer, Familial Male | CDK4/6 Inhibitor | PertuzumabChina
-
West China Second University HospitalRecruitingImmune Checkpoint Inhibitors, CardiotoxicityChina
-
McGill University Health Centre/Research Institute...UnknownChemotherapy, Cancer, Cardiotoxicity, PhysioflowCanada
-
Queen's University, BelfastActive, not recruitingAnthracycline Induced CardiotoxicityUnited Kingdom
-
TC Erciyes UniversityCompletedAnthracycline Induced CardiotoxicityTurkey
Clinical Trials on 2D Echocardiogram
-
Miguel Ayala LeónUnknownCOVID-19 | Hypertension, Pulmonary | Echocardiography, StressMexico
-
RWTH Aachen UniversityUnknown
-
Oklahoma State UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Withdrawn
-
Oklahoma State UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Recruiting
-
Oklahoma State UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Recruiting
-
Duke UniversityRecruiting
-
Barts & The London NHS TrustRecruitingAtrial Fibrillation | Functional Mitral Regurgitation | Functional Tricuspid RegurgitationUnited Kingdom
-
Duke UniversityFogarty International Center of the National Institute of Health; Duke Center... and other collaboratorsCompleted
-
CryoLife, Inc.CompletedAortic Valve Stenosis | Aortic Valve Insufficiency | Pulmonary Valve Insufficiency | Pulmonary Valve StenosisUnited States
-
CryoLife, Inc.CompletedAortic Valve Stenosis | Aortic Valve InsufficiencyUnited States